See more : Pro-Dex, Inc. (PDEX) Income Statement Analysis – Financial Results
Complete financial analysis of Arcadia Biosciences, Inc. (RKDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcadia Biosciences, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Saudi Chemical Holding Company (2230.SR) Income Statement Analysis – Financial Results
- Top Strike Resources Corp. (VENI.CN) Income Statement Analysis – Financial Results
- Crealogix Holding AG (CLXN.SW) Income Statement Analysis – Financial Results
- Alphatec Holdings, Inc. (ATEC) Income Statement Analysis – Financial Results
- Westwing Group SE (WTWGF) Income Statement Analysis – Financial Results
Arcadia Biosciences, Inc. (RKDA)
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.33M | 9.96M | 6.78M | 8.03M | 1.17M | 1.46M | 4.03M | 3.19M | 5.41M | 6.98M | 6.48M | 7.01M |
Cost of Revenue | 3.30M | 9.80M | 8.71M | 5.20M | 885.00K | 661.00K | 283.00K | 895.00K | 892.00K | 2.00M | 673.00K | 909.00K |
Gross Profit | 2.03M | 154.00K | -1.93M | 2.84M | 284.00K | 803.00K | 3.74M | 2.29M | 4.52M | 4.99M | 5.81M | 6.10M |
Gross Profit Ratio | 38.09% | 1.55% | -28.44% | 35.29% | 24.29% | 54.85% | 92.97% | 71.93% | 83.52% | 71.40% | 89.61% | 87.03% |
Research & Development | 1.39M | 1.51M | 3.89M | 7.96M | 7.10M | 6.07M | 7.41M | 8.66M | 8.97M | 10.01M | 8.40M | 7.95M |
General & Administrative | 0.00 | 0.00 | 0.00 | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 14.51M | 18.05M | 22.94M | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
Other Expenses | 73.00K | 33.00K | 10.11M | 105.00K | 466.00K | -3.61M | 281.00K | 340.00K | 521.00K | 0.00 | 5.00K | 8.00K |
Operating Expenses | 15.90M | 19.56M | 26.83M | 24.43M | 20.67M | 17.67M | 18.06M | 20.91M | 20.09M | 20.14M | 16.37M | 16.23M |
Cost & Expenses | 19.27M | 29.36M | 35.54M | 29.63M | 21.55M | 18.33M | 18.34M | 21.81M | 20.98M | 22.14M | 17.04M | 17.14M |
Interest Income | 695.00K | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 747.00K | 1.32M | 2.66M | 1.39M | 626.00K | 186.00K |
Depreciation & Amortization | 287.00K | 1.36M | 1.04M | 662.00K | 194.00K | 154.00K | 279.00K | 304.00K | 294.00K | 358.00K | 391.00K | 378.00K |
EBITDA | -13.58M | -13.65M | -23.27M | -5.44M | -28.67M | -13.32M | -14.66M | -17.98M | -14.98M | -15.39M | -10.17M | -9.74M |
EBITDA Ratio | -254.75% | -228.21% | -270.87% | -259.21% | -1,747.56% | -1,562.64% | -341.65% | -563.86% | -272.40% | -211.90% | -156.99% | -139.00% |
Operating Income | -13.94M | -19.40M | -35.53M | -21.59M | -20.38M | -16.87M | -14.32M | -18.62M | -15.56M | -15.15M | -10.57M | -10.13M |
Operating Income Ratio | -261.50% | -194.89% | -523.98% | -268.76% | -1,743.46% | -1,152.32% | -355.56% | -584.07% | -287.46% | -217.03% | -163.11% | -144.51% |
Total Other Income/Expenses | 781.00K | 3.19M | 19.39M | 6.63M | -9.49M | 3.40M | -1.37M | -979.00K | -2.37M | -1.99M | -621.00K | -178.00K |
Income Before Tax | -13.16M | -15.60M | -16.13M | -6.15M | -28.87M | -13.47M | -15.68M | -19.60M | -17.93M | -17.14M | -11.19M | -10.31M |
Income Before Tax Ratio | -246.85% | -156.67% | -237.94% | -76.55% | -2,469.72% | -920.08% | -389.49% | -614.77% | -331.18% | -245.55% | -172.69% | -147.05% |
Income Tax Expense | 8.00K | 14.00K | 2.00K | -124.00K | 2.00K | 10.00K | 26.00K | 25.00K | 26.00K | 263.00K | 167.00K | 213.00K |
Net Income | -13.98M | -15.61M | -16.13M | -6.03M | -28.87M | -13.48M | -15.71M | -19.62M | -17.96M | -18.34M | -13.20M | -12.37M |
Net Income Ratio | -262.31% | -156.81% | -237.96% | -75.01% | -2,469.89% | -920.77% | -390.14% | -615.56% | -331.66% | -262.66% | -203.69% | -176.46% |
EPS | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
EPS Diluted | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
Weighted Avg Shares Out | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
Weighted Avg Shares Out (Dil) | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
Arcadia Biosciences (RKDA) Announces CFO Transition
Arcadia Biosciences (RKDA) Reports Q3 Loss, Lags Revenue Estimates
Arcadia Biosciences Inc (RKDA) Q3 2022 Earnings Call Transcript
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2022 Financial Results and Business Highlights
New Strong Buy Stocks for October 24th
3 Stocks to Watch in the Promising Agriculture - Products Industry
Arcadia Biosciences (RKDA) Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
Arcadia Biosciences (RKDA) Announces $5.0 Million Registered Direct Offering Priced At-The-Market
Arcadia Biosciences Inc (RKDA) CEO Stan Jacot on Q2 2022 Results - Earnings Call Transcript
Arcadia Biosciences (RKDA) Announces Strong Second-Quarter and First-Half 2022 Financial Results and Business Highlights
Source: https://incomestatements.info
Category: Stock Reports